|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/05/21 OncoCyte Corp. 25 3/05/21 1:21K M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size
1: 25 Notice by an Issuer of the Removal from Listing HTML 14K
and Registration on a Securities Exchange of
Matured, Redeemed or Retired Securities
UNITED STATES |
OMB APPROVAL | |
SECURITIES AND EXCHANGE COMMISSION |
OMB Number: 3235-0080 | |
Washington, D. C. 20549 |
Expires: March 31, 2021 | |
| Estimated average burden | ||
| FORM 25 | hours per response 1.00 |
NOTIFICATION
OF REMOVAL FROM LISTING AND/OR
REGISTRATION UNDER SECTION 12(b) OF THE
SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 1-37648
|
OncoCyte Corporation, NYSE American |
| (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) |
|
15 Cushing, Irvine, California 92618, (949) 409-7600 |
| (Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices) |
|
Common Stock, no par value |
| (Description of class of securities) |
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
| [ ] | 17 CFR 240.12d2-2(a)(1) |
| [ ] | 17 CFR 240.12d2-2(a)(2) |
| [ ] | 17 CFR 240.12d2-2(a)(3) |
| [ ] | 17 CFR 240.12d2-2(a)(4) |
[ ] Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.1
[X] Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
Pursuant to the requirements of the Securities Exchange Act of 1934, OncoCyte Corporation certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
| By |
/s/ Mitchell Levine |
Chief Financial Officer | |||
| Date | Name: Mitchell Levine | Title |
1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
| SEC 1654 (03-06) | Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
C:
| This ‘25’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 3/31/21 | 10-Q | |||
| Filed on / Effective on: | 3/5/21 | CERT | ||
| List all Filings | ||||